Pharmacology of desloratadine: Special characteristics

Clinical Drug Investigation

Volumn 22, Issue SUPPL. 2, 2002, Pages 1-11

  DuBuske, Lawrence M ^a  

^a Immunology Research Institute of New England   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM MAGNESIUM HYDROXIDE; ANTIHISTAMINIC AGENT; AZITHROMYCIN; CETIRIZINE; CIMETIDINE; CYTOCHROME P450; DESLORATADINE; EBASTINE; ERYTHROMYCIN; FEXOFENADINE; FLUOXETINE; GLYCOPROTEIN P; HISTAMINE H1 RECEPTOR; KETOCONAZOLE; LORATADINE; MEPYRAMINE; MIZOLASTINE; ORGANIC ANION TRANSPORT POLYPEPTIDE; POLYPEPTIDE; REDITAB; SEROTONIN 1 ANTAGONIST; TERFENADINE; UNCLASSIFIED DRUG;

ALLERGIC RHINITIS; BINDING AFFINITY; CHRONIC URTICARIA; DRUG ABSORPTION; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG TOLERABILITY; DRUG TOLERANCE; HUMAN; NONHUMAN; PERENNIAL RHINITIS; PHARMACOLOGY; PRIORITY JOURNAL; REVIEW; SIDE EFFECT;

EID: 0036328228     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200222002-00001     Document Type: Review

References (67)

1. Efficacy and safety of once-daily 5mg desloratadine, a potent histamine H1-receptor antagonist, in patients with seasonal allergic rhinitis: Assessment during the spring and fall allergy seasons
2. Once-daily desloratadine reduces the symptoms of perennial allergic rhinitis for at least 4 weeks
3. Desloratadine in the treatment of chronic idiopathic urticaria
4. Decongestant efficacy of desloratadine in patients with seasonal allergic rhinitis
5. Desloratadine reduces nasal congestion in patients with intermittent allergic rhinitis
6. Desloratadine reduces nasal congestion in SAR with greater magnitude than fexofenadine, cetirizine and loratadine
7. Onset and duration of action of desloratadine after controlled pollen challenges in patients with seasonal allergic rhinitis
8. Once-daily desloratadine improves the signs and symptoms of chronic idiopathic urticaria: A randomized, double-blind, placebo-controlled study
9. Absorption and disposition of levocetirizine, the eutomer of cetirizine, administered alone or as cetirizine to healthy volunteers
10. A randomized, double-blind, crossover comparison among cetirizine, levocetirizine, and ucb 28557 on histamine-induced cutaneous responses in healthy adult volunteers
11. Loratadine: A preliminary review of its pharmacodynamic properties and therapeutic efficacy
12. Binding and antiallergic characteristics of desloratadine
13. Desloratadine: A preclinical and clinical overview
14. Role of P-glycoprotein and organic anion transporting polypeptides in drug absorption and distribution: Focus on H1-receptor antagonists
15. The pharmacologic profile of desloratadine: A review
16. Desloratadine: A new nonsedating, oral antihistamine
17. Preclinical pharmacology of desloratadine, a selective and nonsedating histamine H1-receptor antagonist. 1st communication: Receptor selectivity, antihistaminic activity, and antiallergic effects
18. Xerostomia and mydriasis: Two possible side effects associated with descarboxyethoxyloratadine, the main metabolite of loratadine
19. Identification of human liver cytochrome P450 enzymes that metabolize the nonsedating antihistamine loratadine
20. Loratadine. A reappraisal of its pharmacological properties and therapeutic use in allergic disorders
21. Pharmacokinetics and dose proportionality of loratadine
22. Ketoconazole inhibits loratadine metabolism in man
23. Loratadine administered concomitantly with erythromycin: Pharmacokinetic and electrocardiographic evaluations
24. The oral bioavailability of desloratadine is unaffected by food
25. Changes in the pharmacokinetics and electrical pharmacodynamics of terfenadine with concomitant administration of erythromycin
26. Second-generation antihistamines: The risk of ventricular arrhythmias
27. Cardiac ion channels and antihistamines: Possible mechanisms of cardiotoxicity
28. Mechanism of the cardiotoxic actions of terfenadine
29. Arrhythmogenic mechanisms of nonsedating antihistamines
30. In vitro characterization of the inhibition profile of loratadine, desloratadine, and 3-OH-desloratadine for five human cytochrome P-450 enzymes
31. Lack of electrocardiographic effects when desloratadine and ketoconazole are combined
32. Pharmacokinetic and safety profile of desloratadine and fexofenadine when coadministered with azithromycin: A randomized, placebo-controlled, parallel-group study
33. Lack of drug interactions between desloratadine and other common medications
34. Effect of cimetidine on the pharmacokinetics of desloratadine
35. Biochemistry of multidrug resistance mediated by the multidrug transporter
36. Lack of electrocardiographic interaction between desloratadine and erythromycin
37. Cellular localization of the multidrug resistance gene product P-glycoprotein in normal human tissues
38. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites
39. Tissue distribution of P-glycoprotein encoded by a multidrug resistant gene as revealed by a monoclonal antibody, MRK16
40. Hepatic canalicular membrane: 4. Expression of the multidrug resistance genes in the liver
41. The gene encoding multidrug resistance is induced and expressed at high levels during pregnancy in the secretory epithelium of the uterus
42. Inhibition of P-glycoprotein-mediated drug transport: A unifying mechanism to explain the interaction between digoxin and quinidine
43. Absence of the mdrla P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin and cyclosporin A
44. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampicin
45. Effect of desloratadine on P-glycoprotein (P-gp) transport system (MDR1)
46. Optimising drug development: Strategies to assess drug metabolism/transporter interaction potential - Towards a consensus
47. Hepatic disposition of fexofenadine: Influence of the transport inhibitors erythromycin and dibromosulphothalein
48. OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine
49. The effect of rifampicin administration on the disposition of fexofenadine
50. Effects of acute and chronic St John's wort administration on fexofenadine (FEX) disposition
51. St. John's wort induces intestinal and hepatic CYP3A4 and P-glycoprotein in healthy volunteers
52. Identification of functionally variant MDR1 alleles among European Americans and African Americans
53. The PK and PD of fexofenadine in relation to MDR1 genetic polymorphism in Korean healthy subjects
54. Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family
55. Drug-grapefruit juice interactions
56. Grapefruit juice reduces the bioavailability of fexofenadine but not desloratadine
57. Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine
58. Citrus juices are potent inhibitors of intestinal OATP but not p-glycoprotein
59. Modulation by dietary salt of verapamil disposition in humans
60. Modulation of effect of dietary salt on prehepatic first-pass metabolism: Effect of beta-blockade and intravenous salt loading
61. Fexofenadine bioavailability modulated by dietary salt
62. Effect of food on the bioavailability of fexofenadine hydrochloride (MDL 16455A)